Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 14536078
Welcker M, et al. (2003) Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12, 381-92 14536078
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S73-p - CCNE1 (human)
Modsite: AVCADPCsLIPtPDK SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): S73‑p, CCNE1 (mouse): S70‑p, CCNE1 (rat): S73‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

T77-p - CCNE1 (human)
Modsite: DPCsLIPtPDKEDDD SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): T77‑p, CCNE1 (mouse): T74‑p, CCNE1 (rat): T77‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Downstream Regulation
Effect of modification (function):  protein degradation

S387-p - CCNE1 (human)
Modsite: LsEQNRAsPLPSGLL SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): S387‑p, CCNE1 (mouse): S385‑p, CCNE1 (rat): S388‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, phosphopeptide mapping, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK2 (human)
Downstream Regulation
Effect of modification (function):  protein degradation

T395-p - CCNE1 (human)
Modsite: PLPSGLLtPPQsGKK SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): T395‑p, CCNE1 (mouse): T393‑p, CCNE1 (rat): T396‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, phosphopeptide mapping, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
KINASE CDK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3A (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CDK2 (human) transfection of inactive enzyme, inhibition of upstream enzyme, transfection of wild-type enzyme
KINASE GSK3B (human) transfection of inactive enzyme, pharmacological activator of upstream enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
LY294002 increase

S399-p - CCNE1 (human)
Modsite: GLLtPPQsGKKQSSG SwissProt Entrez-Gene
Orthologous residues
CCNE1 (human): S399‑p, CCNE1 (mouse): S397‑p, CCNE1 (rat): S400‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, phosphopeptide mapping, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK2 (human) transfection of inactive enzyme, inhibition of upstream enzyme, transfection of wild-type enzyme
Downstream Regulation
Effect of modification (function):  protein degradation